340B Program 101: What It Is and How It Works

Are you part of a Federally Qualified Health Center (FQHC) or Community Health Center (CHC) and looking to extend your services without stretching your budget?

What Is the 340B Program?

The 340B program, a federal initiative since 1992, lets eligible healthcare providers like FQHCs buy covered outpatient drugs at statutorily discounted prices. Because most payer reimbursement is not tied to that discounted acquisition cost, the difference between what an entity pays and what it is reimbursed becomes savings the organization can reinvest in patient care and expanded services. Reimbursement varies by payer, and Medicaid fee-for-service is generally paid at actual acquisition cost plus a dispensing fee, so 340B savings on those claims are typically minimal.

This initiative supports FQHCs by allowing them to reinvest 340B savings, serve a broader patient base and provide more comprehensive services while managing costs effectively.

Despite the benefits of the 340B Program, the requirements are complex and ever-changing, so many healthcare providers struggle with managing their 340B program effectively. Fortunately, the team at Remy has decades of experience when it comes to implementing and managing effective 340B programs.

Here's a quick primer on what you need to know about the 340B program and how it works:

What exactly does the 340B program entail? Initiated under the Public Health Service Act, it provides substantial drug price discounts to covered entities, including FQHCs, enabling healthcare organizations to enhance care for underserved populations and reallocate savings towards improved health services.

The Goal of the 340B Drug Pricing Program

The primary goal is to support safety-net providers like Community Health Centers and FQHCs, enhancing care for vulnerable populations through cost savings on outpatient drugs. These savings can be used to expand healthcare services, enhance care quality and improve patient outcomes.

By accessing discounted medications, the 340B program helps FQHCs extend their limited resources, enabling investment in new technologies and improved patient care facilities.

How Does the 340B Program Work?

In practice, an eligible covered entity registers in OPAIS and recertifies annually, buys covered outpatient drugs at statutorily discounted prices, and must make sure those drugs are dispensed only to 340B-eligible patients. Savings come from the difference between that discounted acquisition cost and reimbursement, which varies by payer. Keeping the benefit depends on following the program rules below, and violations can result in removal from the program.

340B Compliance Requirements

Adherence to 340B Program guidelines is crucial. Covered entities need to adhere to several rules, including:

• Maintaining Accurate Records: Keeping detailed and accurate records is crucial for tracking the dispensation and inventory of 340B drugs.
• Preventing Duplicate Discounts: The statutory prohibition is specific to Medicaid - a manufacturer cannot be required to provide both a 340B discount and a Medicaid rebate on the same drug. Covered entities manage this through the carve-in/carve-out decision, which determines whether 340B drugs are dispensed to Medicaid fee-for-service patients and is recorded in the Medicaid Exclusion File in OPAIS. Medicaid managed care is handled separately and the required approach varies by state, so entities need to confirm their state's billing and identification rules.
• Ensuring Drugs are Dispensed to Eligible Patients Only: Covered entities must have robust verification processes to confirm that 340B drugs are dispensed only to patients who are eligible under the program's guidelines. This helps ensure the benefits of the program reach the intended individuals.
• Conducting Regular Internal Audits: Regular audits are recommended to assess the compliance of the 340B program's operations. These audits help identify and rectify discrepancies in drug dispensation and compliance, ensuring the program runs efficiently and stays within federal guidelines.
• Implementing Training Programs: Providing ongoing training programs for staff involved in the 340B program is vital. Training ensures that all personnel are up-to-date on the latest program requirements and best practices, which is key to maintaining program integrity and effectiveness.

340B Program Audits Explained

Ensuring compliance through regular audits is essential for maintaining the integrity of the 340B program and for an organization's continued involvement with the program.

Audits verify compliance with program regulations, helping providers identify and rectify areas of potential non-compliance.

HRSA audits are demanding, but they are manageable for entities that document consistently and can produce records on request. Findings are common, and they cluster in a few predictable areas: drug diversion to ineligible patients, duplicate discounts on Medicaid claims, and inaccurate entity, child site or contract pharmacy records in OPAIS. Knowing where auditors look most often is the practical starting point for preparation.

Common 340B Audit Challenges

Federally Qualified Health Centers (FQHCs) and Community Health Centers (CHCs) often encounter challenges that can complicate compliance with the 340B program. These challenges typically include:

• Incorrect Record-Keeping: This issue can arise from inadequate tracking systems or human error, leading to discrepancies in drug inventory and patient records. Health centers need to utilize sophisticated record-keeping systems that ensure accuracy and transparency in documenting drug dispensations and patient eligibility.
• Dispensing Drugs to Ineligible Patients: Sometimes, drugs may inadvertently be dispensed to patients who do not meet the 340B eligibility criteria. To prevent this, FQHCs should implement strict verification processes that confirm patient eligibility before drugs are dispensed. This includes regular training for staff on the latest eligibility requirements and the use of technology to automate eligibility checks.

Proactively addressing these issues through regular audits can help mitigate risks and enhance compliance. Audits should be scheduled regularly and involve a thorough review of both physical and digital records.

Violating these or other Program rules can result in a Center being removed from the program. Responsibility for 340B compliance always rests with the covered entity, but working with a 340B consultant like Remy can strengthen your policies, monitoring and audit readiness so that responsibility is easier to carry.

340B Audit Preparation

Effective audit preparation is crucial for FQHCs to ensure compliance with the 340B program and facilitate smooth audit processes. Best practices include:

• Maintaining Detailed and Accurate Records: Establishing and maintaining a robust record-keeping system is vital. This system should be capable of capturing all transactions related to 340B drugs, including procurement, dispensation, and patient records. Regular updates and backups of these records are essential to safeguard information and provide easy access during audits.
• Conducting Regular Internal Reviews: FQHCs should conduct internal reviews periodically before an external audit occurs. These reviews can help identify any potential compliance issues early on and allow for corrective actions to be taken on time. It's beneficial to involve multiple layers of staff in the review process to maintain a comprehensive audit trail.

Implementing these practices prepares you for audits and builds a foundation of compliance and accountability within the organization. This proactive approach reduces the risk of non-compliance and ensures that the benefits of the 340B program are fully realized by the community health centers.

340B Program Eligibility

Understanding the eligibility criteria for the 340B program is crucial for healthcare providers looking to benefit from its offerings. Here's a breakdown of the criteria:

Types of Eligible Entities

The 340B program is open to various healthcare entities known as covered entities. These include:

• Federally Qualified Health Centers (FQHCs): Organizations that provide primary care in underserved areas.
• Disproportionate Share Hospitals (DSHs): Hospitals that serve many low-income patients.
• Children's Hospitals: Facilities that provide extensive pediatric care.
• Critical Access Hospitals: Rural hospitals that meet CMS criteria for limited bed count and 24/7 emergency care.
• Sole Community Hospitals and Rural Referral Centers: Rural hospitals holding these Medicare designations, subject to the applicable disproportionate share adjustment threshold.
• Freestanding Cancer Hospitals: Cancer hospitals exempt from the Medicare prospective payment system.
• Ryan White HIV/AIDS Program Grantees: Programs and clinics funded under the Ryan White HIV/AIDS Program.
• Hemophilia Treatment Centers: Federally funded comprehensive hemophilia diagnostic and treatment centers.
• Specialized Clinics: Clinics such as STD clinics, TB clinics, black lung clinics, and Title X family planning clinics that receive federal funding.

These entities are integral to providing healthcare in resource-limited settings and qualify due to their critical role in public health.

Specific 340B Eligibility Requirements

Eligibility is statutory. An organization qualifies because it holds one of the federal statuses or designations listed in the 340B statute, not because it meets a general test of mission or need. For health centers, the criteria include:

• Qualifying Federal Status: For FQHCs, 340B eligibility comes from receiving a Public Health Service Act Section 330 grant, or from holding FQHC look-alike designation. Other covered entity types qualify through their own statutory route, such as a Medicare DSH adjustment percentage above the applicable threshold for hospitals, or funding under a named federal program such as Ryan White.
• Registration and Recertification: Eligible entities must register with the 340B program through the Office of Pharmacy Affairs Information System (OPAIS) and undergo annual recertification to verify compliance.

Reinvestment is the statute's purpose rather than a reporting requirement. Congress created 340B so that covered entities could stretch scarce federal resources and reach more eligible patients with comprehensive services, and HRSA does not currently require covered entities to report how they spend their 340B savings. Separately, Section 330 grantees carry their own program obligations - including serving patients regardless of ability to pay and operating a sliding fee scale - which are distinct from 340B eligibility criteria.

Determining 340B Eligibility

Healthcare providers can determine their eligibility through a step-by-step process:

• Review HRSA Guidelines: The first step is to thoroughly review the Health Resources and Services Administration (HRSA) guidelines to understand all necessary compliance and operational requirements.
• Consultation with 340B Experts: Consulting with expert consultants, like Remy, or legal advisors who specialize in 340B regulations can provide clarity and assist in navigating the complexities of eligibility and compliance.
• Verify Your OPAIS Records: The 340B OPAIS is a registration and database system, not a self-assessment tool. Use it to confirm that your entity record, child sites and contract pharmacy listings are accurate and current, since stale records are a frequent source of audit findings. For structured self-assessment, use the self-audit and policy resources published by Apexus, the HRSA-designated 340B Prime Vendor.

If your practices don't fully align, the team at Remy Healthcare can assess your operational readiness and help you close the gaps before you register or recertify. Eligibility itself is set by statute and determined by HRSA - no consultant can confer it.

• Documentation and Record-Keeping: Gather and prepare all necessary documentation that demonstrates eligibility, including financial records, patient care statistics, and compliance reports with federal healthcare regulations.

Contract Pharmacy and the GPO Prohibition

Two operational realities shape almost every 340B program, and neither is obvious from the statute alone.

Contract pharmacy. A covered entity that lacks an in-house pharmacy - or that wants to reach patients closer to home - can contract with one or more outside pharmacies to dispense 340B drugs on its behalf. HRSA guidance permits these arrangements, but the covered entity remains responsible for the drugs: it needs a written contract, the pharmacy must be registered in OPAIS before 340B purchases flow to it, and the entity has to reconcile dispensing data to confirm that only eligible patients received 340B inventory.

Manufacturer contract pharmacy restrictions. Since 2020, a large number of manufacturers have unilaterally restricted 340B pricing through contract pharmacies, typically limiting entities to a single contract pharmacy or conditioning access on submitting claims data. Litigation over these restrictions is ongoing and the policies change frequently, so entities should track each manufacturer's current terms rather than assume last year's arrangement still holds. Some manufacturers have also moved toward rebate-based models instead of upfront discounts - see what covered entities need to know about the 340B rebate model for how that changes cash flow and data requirements.

The GPO prohibition. Certain hospital covered entities may not use a group purchasing organization to buy covered outpatient drugs. This restriction applies to disproportionate share hospitals, children's hospitals, and freestanding cancer hospitals. It does not apply to FQHCs, FQHC look-alikes, critical access hospitals, sole community hospitals, rural referral centers, or the grantee entity types - those entities may continue to use GPO pricing where it is advantageous.

Maximizing 340B Benefits

The 340B program offers invaluable opportunities for Federally Qualified Health Centers, Community Health Centers, and other covered entities to enhance patient care through significant cost savings. By understanding and adhering to the program's requirements, FQHCs can expand their services and improve overall patient outcomes.

Are you ready to leverage the 340B program to its fullest? Contact us today for a free consultation to assess your FQHC's readiness for the 340B program - HRSA determines eligibility, and we help you get the operations, records and documentation in shape to support it.